QT interval and arrhythmic safety of hydroxychloroquine monotherapy in coronavirus disease 2019
Background: Observational studies have suggested increased arrhythmic and cardiovascular risk with the combination use of hydroxychloroquine (HCQ) and azithromycin in patients with coronavirus disease 2019 (COVID-19). Objective: The arrhythmic safety profile of HCQ monotherapy, which remains under i...
Päätekijät: | , , , , , , , , |
---|---|
Aineistotyyppi: | Artikkeli |
Kieli: | English |
Julkaistu: |
Elsevier
2020-08-01
|
Sarja: | Heart Rhythm O2 |
Aiheet: | |
Linkit: | http://www.sciencedirect.com/science/article/pii/S2666501820300751 |